Targeted Strategies in the Treatment of Metastatic Colon Cancer

Authors: Diane Reidy MD, MS1 and Leonard Saltz MD1
View More View Less
  • 1 From the Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.

Advances in the understanding of tumor biology have led to the identification of important cellular processes involved in the pathogenesis of colon cancer. Drugs that interfere with these critical pathways are known as targeted agents. The goal of these therapies is to selectively interrupt the signal transduction pathways responsible for tumor growth and survival. Some of these targeted agents have made important, albeit modest, contributions to the treatment of patients with metastatic colorectal cancer. However, the activity levels with the currently available targeted therapies are far lower than experts had hoped, and toxicities are often nontrivial. This article reviews the available therapies, the data that justify their use, and the challenges of optimizing targeted therapies through combinations with cytotoxic chemotherapies and other targeted agents. Finally, some newer drugs and strategies currently being tested in clinical trials are discussed.

Correspondence: Leonard Saltz, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-917, New York, NY 10021. E-mail: saltzl@mskcc.org
  • 1.

    Buroker TR, O'Connell MJ, Wieand HS et al. . Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:1420.

    • Search Google Scholar
    • Export Citation
  • 2.

    Tournigand C, Andre T, Achille E et al. . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229237.

    • Search Google Scholar
    • Export Citation
  • 3.

    Punt CJ, Koopman M, Douma J et al. . Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): a Dutch Colorectal Cancer Group (DCCG) phase III study [abstract]. J Clin Oncol 2007;25(Suppl 1):166s. Abstract 4012.

    • Search Google Scholar
    • Export Citation
  • 4.

    Jain RK, Duda DG, Clark JW et al. . Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:2440.

  • 5.

    Manegold J, von Pawel P, Zatloukal R et al. . Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naíve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract]. J Clin Oncol 2007;25(Suppl 1):388s. Abstract LBA7514.

    • Search Google Scholar
    • Export Citation
  • 6.

    Reidy D, Chung KY, Timoney JP et al. . Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007;25:26912695.

  • 7.

    Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. . Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:6065.

    • Search Google Scholar
    • Export Citation
  • 8.

    Hurwitz H, Fehrenbacher L, Novotny W et al. . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:23352342.

    • Search Google Scholar
    • Export Citation
  • 9.

    Saltz LB, Clarke S, Diaz-Rubio E et al. . Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC) [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando, Florida. Abstract 238.

    • Search Google Scholar
    • Export Citation
  • 10.

    Saltz LB, Clarke S, Diaz-Rubio E et al. . Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. J Clin Oncol 2007;25(Suppl 1):170s Abstract 4028.

    • Search Google Scholar
    • Export Citation
  • 11.

    Giantonio BJ, Catalano PJ, Meropol NJ et al. . High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. J Clin Oncol 2005;23(Suppl 1):1s. Abstract 2.

    • Search Google Scholar
    • Export Citation
  • 12.

    Grothey A, Sugrue M, Hedrick E et al. . Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) [abstract]. J Clin Oncol 2007;25(Suppl 1):172s. Abstract 4036.

    • Search Google Scholar
    • Export Citation
  • 13.

    Saltz L, Rubin M, Hochster H. Cetuximab plus irinotecan is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor [abstract]. J Clin Oncol 2001;20(Suppl 1): Abstract 7.

    • Search Google Scholar
    • Export Citation
  • 14.

    Saltz LB, Meropol NJ, Loehrer PJ et al. . Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer that expresses the epidermal growth factor receptor [abstract]. J Clin Oncol 2002;21(Suppl 1): Abstract 504.

    • Search Google Scholar
    • Export Citation
  • 15.

    Cunningham D, Humblet Y, Siena S et al. . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337345.

    • Search Google Scholar
    • Export Citation
  • 16.

    Camp ER, Summy J, Bauer TW et al. . Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005;11:397405.

    • Search Google Scholar
    • Export Citation
  • 17.

    Jonker DJ, Karapetis CS, Moore M et al. . Randomized phase III trial of cetuximab monotherapy plus best supportive care versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (ACITC) [abstract]. Presented at the 2007 American Association of Cancer Research Annual Meeting; April 14–18, 2007; Los Angeles, California. B-1a.

    • Search Google Scholar
    • Export Citation
  • 18.

    Van Cutsem E, Nowacki M, Lang I et al. . Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial [abstract]. J Clin Oncol 2007;25(Suppl 1):164s. Abstract 4000.

    • Search Google Scholar
    • Export Citation
  • 19.

    Hecht JR, Patnaik A, Malik I et al. . ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis [abstract]. J Clin Oncol 2004;22(Suppl 1): Abstract 3511.

    • Search Google Scholar
    • Export Citation
  • 20.

    Berlin J, Neubauer M, Swanson P et al. . Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr) [abstract]. J Clin Oncol 2006;24(Suppl 1):158s. Abstract 3548.

    • Search Google Scholar
    • Export Citation
  • 21.

    Van Cutsem E, Peeters M, Siena S et al. . An open label phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer. J Clin Oncol 2007;25:16581664.

    • Search Google Scholar
    • Export Citation
  • 22.

    Amgen. Amgen discontinues Vectibix(TM) treatment in PACCE trial evaluating Vectibix(TM) as part of triple combination regimen. Press Release 3/22/2007. Available at http://www.amgen.com/media/media_pr_detail.jsp?releaseID=977186. Accessed August 28, 2007.

    • Search Google Scholar
    • Export Citation
  • 23.

    Engstron PF, Arnoletti JP, Benson AB III et al. . NCCN Colon Cancer guidelines, version 2, 2007. Available at http://www.nccn.org/professionals/physician_gls/default.asp. Accessed August 28, 2007.

    • Search Google Scholar
    • Export Citation
  • 24.

    Saltz LB. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. J Clin Oncol 2003;22(Suppl 1): Abstract 817.

    • Search Google Scholar
    • Export Citation
  • 25.

    Saltz LB, Perez-Soler R. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:52355246.

    • Search Google Scholar
    • Export Citation
  • 26.

    Saltz L, Easley C, Kirkpatrick P. Panitumumab. Nat Rev Drug Discov 2006;5:987988.

  • 27.

    Chung KY, Fusco A, Park R. Evaluation of routine antihistamine premedication after the first 2 doses of cetuximab [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando, Florida. Abstract 357.

    • Search Google Scholar
    • Export Citation
  • 28.

    Allen RM, Goldberg RM, Berlin J et al. . Unusually high rates of hypersensitivity to cetuximab in the middle-southern United States: association with atopic phenotype [abstract]. J Clin Oncol 2007;25(Suppl 1):505s. Abstract 9051.

    • Search Google Scholar
    • Export Citation
  • 29.

    Tonra JR, Deevi DS, Corcoran E et al. . Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006;12(7 Pt 1):21972207.

    • Search Google Scholar
    • Export Citation
  • 30.

    Saltz LB, Lenz HJ, Hochster H et al. . Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer: the ``BOND-2'' study. J Clin Oncol, in press.

    • Search Google Scholar
    • Export Citation
  • 31.

    Lenz HJ, Marshall J, Rosen L et al. . Phase II trial of SU11248 in patients with metastatic colorectal cancer (MCRC) after failure of standard chemotherapy [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 26–28, 2007; San Francisco, California. Abstract 241.

    • Search Google Scholar
    • Export Citation
  • 32.

    Leong S, Eckhardt G, Chan E et al. . A phase I study of sunitinib in combination with modified FOLFOX 6 (mFOLFOX6) chemotherapy [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando, Florida. Abstract 285.

    • Search Google Scholar
    • Export Citation
  • 33.

    Starling N, Cunningham D, Vazquez F et al. . A phase I study of sunitinib in combination with FOLFIRI chemotherapy in treatment-naive, metastatic colorectal cancer [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando, Florida. Abstract 319.

    • Search Google Scholar
    • Export Citation
  • 34.

    Hecht R, Trarbach T, Jaeger E et al. . A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK222584 or placebo (CONFIRM1) [abstract]. J Clin Oncol 2005;23(Suppl 1):LBA3. Abstract 3.

    • Search Google Scholar
    • Export Citation
  • 35.

    Koehne C, Bajetta E, Lin E et al. . Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK222584 (PRT/ZK) or placebo (CONFIRM2) [abstract]. J Clin Oncol 2006;24(Suppl 1):148s. Abstract 3508.

    • Search Google Scholar
    • Export Citation
  • 36.

    Rothenberg ML, Lafleur B, Levy DE et al. . Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:92659274.

    • Search Google Scholar
    • Export Citation
  • 37.

    Keilholz U, Arnold D, Niederle N et al. . Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial [abstract]. J Clin Oncol 2005;23(Suppl 1):264s. Abstract 3575.

    • Search Google Scholar
    • Export Citation
  • 38.

    Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR. Mol Cancer Res 2005;5:203220.

  • 39.

    Baselga J, Schoffski P, Rojo F et al. . A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G) in patients with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2006;24(Suppl 1):122s. Abstract 3006.

    • Search Google Scholar
    • Export Citation
  • 40.

    LeRoith D, Helman L. The new kid on the block (ade) of the IGF-1 receptor. Cancer Cell 2004;5:201202.

  • 41.

    Tabernero J, Rojo F, Burris H et al. . A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol 2005;23(Suppl 1):193s. Abstract 3007.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 72 16 2
PDF Downloads 51 20 1
EPUB Downloads 0 0 0